MARKET

TGTX

TGTX

Tg Therapeutics Inc
NASDAQ
33.93
+0.28
+0.83%
After Hours: 34.00 +0.07 +0.21% 19:57 12/06 EST
OPEN
33.82
PREV CLOSE
33.65
HIGH
34.75
LOW
33.63
VOLUME
1.32M
TURNOVER
--
52 WEEK HIGH
36.84
52 WEEK LOW
12.84
MARKET CAP
5.28B
P/E (TTM)
-317.9944
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TGTX last week (1125-1129)?
Weekly Report · 4d ago
TG Therapeutics to Participate in the Evercore HealthCONx Conference
Barchart · 11/29 07:00
TG Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Benzinga · 11/25 16:00
TG Therapeutics Price Target Raised to $43.00/Share From $30.00 by JP Morgan
Dow Jones · 11/25 14:32
TG Therapeutics Is Maintained at Overweight by JP Morgan
Dow Jones · 11/25 14:32
JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $43
Benzinga · 11/25 14:22
Weekly Report: what happened at TGTX last week (1118-1122)?
Weekly Report · 11/25 11:48
TG Therapeutics price target raised to $43 from $30 at JPMorgan
TipRanks · 11/25 11:45
More
About TGTX
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.

Webull offers TG Therapeutics Inc stock information, including NASDAQ: TGTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TGTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TGTX stock methods without spending real money on the virtual paper trading platform.